Image For Activity Cover
Emerging Therapeutics Summit 2019
Overview
The Emerging Therapeutics Summit is a highlighted program that will cover what is new and up-coming over the next 5 years in therapeutic modalities that will transform the practice of cardiac electrophysiology and revolutionize methods utilized to treat heart rhythm disturbances. This Multidisciplinary Summit will cover the latest innovations and potential applications of new technological advances in device therapy, biologic and pharmacologic therapy, mapping of arrhythmias, and ablation. 
Session Information
S-ET01. Emerging Therapeutics Summit: Device Technology Roundtable - Innovations in CIEDs
Co-Chairs: Jeanne E.. Poole, MD, FHRS, CCDS. Univ of Washington School of Medicine, Seattle, WA  and Ulrika Maria. Birgersdotter-Green, MD, FHRS. UC San Diego Health Systems, La Jolla, CA  

The first session will involve a Case Based Round Table Discussion involving illustrative cases reflecting current challenges and future opportunities in device-based technology a panel of leading experts at the cutting edge of innovation, research, and development. Topics to be discussed include next generations leadless and lead technology, advances in His bundle and LV endocardial pacing, cardiac contractility, evolutions in subcutaneous ICD technology, wearable external defibrillation, and technological advancements in external monitoring and resuscitation.

S-ET02. Emerging Therapeutics Summit: Developing Chamber-Specific Myocardial Preparations for Drug and Disease Testing
Co-chairs: Mark E.. Anderson, MD, FHRS. Johns Hopkins University Dept Of Medicine, Baltimore, MD, and  L. Lee Eckhardt, MD, FHRS. University of Wisconsin, Schoo, Madison, WI     

 

This session will feature state-of-the art futuristic talks by leading experts who are at the cutting edge of research and development of novel biologic and pharmacologic approaches for the treatment of heart rhythm disorders, which have the potential to disrupt traditional device- and ablation- based approaches to treatment of arrhythmias.

S-ET03. Emerging Therapeutics Summit: Ablation Part I - Future of Arrhythmia Mapping
Co-chairs:Jonathan M.. Kalman, MBBS, PhD, FHRS. Royal Melbourne Hospital, Australia and Isabel Deisenhofer, MD. German Heart Center Munich Dep, Munich, Germany    

 

 This session will feature state-of-the art talks by leading experts who are at the cutting edge of research and innovation in the field of arrhythmia and substrate mapping on advances that will have a major impact on future ablation strategies and risk stratification approaches. Each lecture will be followed by an opportunity for questions from the audience.

S-ET04. Emerging Therapeutics Summit: Ablation Part II - Technologic Ablative Therapy
Co-chairs:  David J.. Callans, MD, FHRS, CCDS. Hospital of the Univ of Pennsylvania, Washington Crossing, PA  and Kyoko Soejima, MD. Kyorin University School of Medicine, Japan  

This session will feature state-of-the art talks by experts who are at the forefront of innovation and advances in ablation technology that will transform the field over the next 5-years. These leading experts will then participate in a panel discussion with interaction from the audience on the future of ablation for cardiac arrhythmias.

 

 

 
Accreditation
The Heart Rhythm Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Heart Rhythm Society designates this activity for a maximum of 6.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Summary
Availability: On-Demand
Cost: Member: $75.00
Non-Member: $150.00
Credit Offered: 5.5 ABIM-MOC Credits
5.5 ABP-MOC Credits
5.5 CME Credits
5.5 COP Credits
Contains: 4 Courses
  Heart Rhythm Society
1325 G Street NW, Suite 400
Washington, DC 20005
P: 202-464-3400 F: 202-464-3401 E: info@HRSonline.org
© Heart Rhythm Society 2019
Privacy Policy | Linking Policy | Patient Education Disclaimer | State Nonprofit Disclosures
 
Powered By